To explore the role of single-nucleotide polymorphisms (SNPs) in hsa-miR-9 in non-small cell lung cancer (NSCLC).
Methods:
Log-rank and Cox regression analyses were conducted to assess the association of four functional SNPs of miR-9 with overall survival (OS) of Chinese patients with NSCLC. A reporter luciferase assay was performed to examine the relationship between the SNPs and transcriptional activity of miR-9. The expression of miR-9 in cells was detected by quantitative real-time PCR assay. Xenograft model was established in nude mice, which were treated with Lv-MiR-9-mimics or Lv-miR-9-inhibitor. A long noncoding RNA (lncRNA)-miR-9-messenger RNA (mRNA) competing endogenous RNA (ceRNA) network was established based on bioinformatics analyses.
Results:
We found that rs1501672 was associated with the prognosis of 1001 Chinese NSCLC patients (A>G, additive model: adjusted hazard ratio = 0.89, 95% confidence interval = 0.79–1.00, p = 0.056). Luciferase reporter assay showed higher luciferase activity with wild A allele than that with mutant G allele in 293T, SPC-A1, and A549 cell lines. The miR-9 level was significantly higher in lung cancer cells than normal lung cells. miR-9 was also over expressed in lung cancer tissue according to The Cancer Genome Atlas and gene expression omnibus databases. Xenograft models based on H1299 cells showed that lv-miR-9-inhibitor significantly decreased tumor growth compared with the lv-miR-9-NC group (p < 0.001). Bioinformatics analysis showed that one target gene leukemia inhibitory factor receptor and two lncRNAs (KIAA0087 and GVINP1) were associated with OS of NSCLC patients.
Conclusion:
The rs1501672 of miR-9 was associated with the prognosis of NSCLC patients in the Chinese population. The lncRNA-miR-9-mRNA ceRNA network revealed potential molecular biological regulation pathways and prognostic biomarkers for NSCLC.
Get full access to this article
View all access options for this article.
References
1.
ArbourK.C., and RielyG.J. (2019). Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA, 322, 764–774.
2.
AsselahT. (2010). Genetic polymorphism and response to treatment in chronic hepatitis C: the future of personalized medicine. J Hepatol, 52, 452–454.
3.
BegM.S., BrennerA.J., SachdevJ., BoradM., KangY.K., StoudemireJ., et al. (2017). Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs, 35, 180–188.
4.
ChenD., SunY., WeiY., ZhangP., RezaeianA.H., Teruya-FeldsteinJ., et al. (2012). LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med, 18, 1511–1517.
5.
ChenX., ZhuL., MaZ., SunG., LuoX., LiM., et al. (2015). Oncogenic miR-9 is a target of erlotinib in NSCLCs. Sci Rep, 5, 17031.
6.
EulalioA., HuntzingerE., and IzaurraldeE. (2008). Getting to the root of miRNA-mediated gene silencing. Cell, 132, 9–14.
7.
FanK., WangX., ZhangJ., RamosR.I., ZhangH., LiC., et al. (2017). Hypomethylation of CNTFRalpha is associated with proliferation and poor prognosis in lower grade gliomas. Sci Rep, 7, 7079.
8.
HellerG., WeinzierlM., NollC., BabinskyV., ZieglerB., AltenbergerC., et al. (2012). Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin Cancer Res, 18, 1619–1629.
9.
HouR., KongX., YangB., XieY., and ChenG. (2017). SLC14A1: a novel target for human urothelial cancer. Clin Transl Oncol, 19, 1438–1446.
10.
HuZ., ShuY., ChenY., ChenJ., DongJ., LiuY., et al. (2011). Genetic polymorphisms in the precursor MicroRNA flanking region and non-small cell lung cancer survival. Am J Respir Crit Care Med, 183, 641–648.
11.
JinX., GuanY., ZhangZ., and WangH. (2020). Microarray data analysis on gene and miRNA expression to identify biomarkers in non-small cell lung cancer. BMC Cancer, 20, 329.
12.
KoutrosS., BarisD., FischerA., TangW., Garcia-ClosasM., KaragasM.R., et al. (2013). Differential urinary specific gravity as a molecular phenotype of the bladder cancer genetic association in the urea transporter gene, SLC14A1. Int J Cancer, 133, 3008–3013.
13.
LeeR.C., FeinbaumR.L., and AmbrosV. (1993). The, C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75, 843–854.
14.
LiG., WuF., YangH., DengX., and YuanY. (2017). MiR-9-5p promotes cell growth and metastasis in non-small cell lung cancer through the repression of TGFBR2. Biomed Pharmacother, 96, 1170–1178.
15.
LiP., XingW., XuJ., YuanD., LiangG., LiuB., et al. (2019). microRNA-301b-3p downregulation underlies a novel inhibitory role of long non-coding RNA MBNL1-AS1 in non-small cell lung cancer. Stem Cell Res Ther, 10, 144.
16.
LiaoX., HuangK., HuangR., LiuX., HanC., YuL., et al. (2017). Genome-scale analysis to identify prognostic markers in patients with early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy. Onco Targets Ther, 10, 4493–4506.
17.
LujambioA., CalinG.A., VillanuevaA., RoperoS., Sanchez-CespedesM., BlancoD., et al. (2008). A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A, 105, 13556–13561.
18.
MegiorniF., PizzutiA., and FratiL. (2011). Clinical significance of microRNA expression profiles and polymorphisms in lung cancer development and management. Patholog Res Int, 2011, 780652.
19.
NourmohammadiB., TafsiriE., RahimiA., NourmohammadiZ., Daneshvar KakhakiA., ChoW., et al. (2019). Expression of miR-9 and miR-200c, ZEB1, ZEB2 and E-cadherin in non-small cell lung cancers in Iran. Asian Pac J Cancer Prev, 20, 1633–1639.
20.
OkayamaA., MiyagiY., OshitaF., ItoH., NakayamaH., NishiM., et al. (2015). Identification of tyrosine-phosphorylated proteins upregulated during epithelial-mesenchymal transition induced with TGF-beta. J Proteome Res, 14, 4127–4136.
21.
PilyuginM., and Irminger-FingerI. (2014). Long non-coding RNA and microRNAs might act in regulating the expression of BARD1 mRNAs. Int J Biochem Cell Biol, 54, 356–367.
22.
RyanB.M., RoblesA.I., and HarrisC.C. (2010). Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer, 10, 389–402.
23.
SalmenaL., PolisenoL., TayY., KatsL., and PandolfiP.P. (2011). A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell, 146, 353–358.
24.
SenyukV., ZhangY., LiuY., MingM., PremanandK., ZhouL., et al. (2013). Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis. Proc Natl Acad Sci U S A, 110, 5594–5599.
25.
ShannonP., MarkielA., OzierO., BaligaN.S., WangJ.T., RamageD., et al. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res, 13, 2498–2504.
26.
ShaoJ., ZhuW., DingY., ZhuH., JingX., YuH., et al. (2019). Phosphorylation of LIFR promotes prostate cancer progression by activating the AKT pathway. Cancer Lett, 451, 110–121.
27.
SiegelR.L., MillerK.D., and JemalA. (2018). Cancer statistics, 2018. CA Cancer J Clin, 68, 7–30.
28.
SlabyO., LagaR., and SedlacekO. (2017). Therapeutic targeting of non-coding RNAs in cancer. Biochem J, 474, 4219–4251.
29.
SromekM., GlogowskiM., ChechlinskaM., KulinczakM., SzafronL., ZakrzewskaK., et al. (2017). Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection. Cell Oncol (Dordr), 40, 529–536.
30.
SuiJ., LiY.H., ZhangY.Q., LiC.Y., ShenX., YaoW.Z., et al. (2016). Integrated analysis of long non-coding RNAassociated ceRNA network reveals potential lncRNA biomarkers in human lung adenocarcinoma. Int J Oncol, 49, 2023–2036.
31.
SuiJ., YangS., LiuT., WuW., XuS., YinL., et al. (2019). Molecular characterization of lung adenocarcinoma: a potential four-long noncoding RNA prognostic signature. J Cell Biochem, 120, 705–714.
32.
ThomsonD.W., and DingerM.E. (2016). Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet, 17, 272–283.
33.
TsaprouniL.G., YangT.P., BellJ., DickK.J., KanoniS., NisbetJ., et al. (2014). Cigarette smoking reduces DNA methylation levels at multiple genomic loci but the effect is partially reversible upon cessation. Epigenetics, 9, 1382–1396.
34.
VoliniaS., CalinG.A., LiuC.G., AmbsS., CimminoA., PetroccaF., et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A, 103, 2257–2261.
35.
WangH., WuQ., ZhangY., ZhangH.N., WangY.B., and WangW. (2017). TGF-beta1-induced epithelial-mesenchymal transition in lung cancer cells involves upregulation of miR-9 and downregulation of its target, E-cadherin. Cell Mol Biol Lett, 22, 22.
36.
WangR., ChenX.F., and ShuY.Q. (2015). Prediction of non-small cell lung cancer metastasis-associated microRNAs using bioinformatics. Am J Cancer Res, 5, 32–51.
37.
WuS., ShenW., PanY., ZhuM., XieK., GengL., et al. (2015). Genetic variations in key microRNAs are associated with the survival of nonsmall cell lung cancer. Medicine (Baltimore), 94, e2084.
38.
WuS., ShenW., YangL., ZhuM., ZhangM., ZongF., et al. (2019). Genetic variations in miR-125 family and the survival of non-small cell lung cancer in Chinese population. Cancer Med, 8, 2636–2645.
39.
XuJ., QianY., YeM., FuZ., JiaX., LiW., et al. (2016). Distinct expression profile of lncRNA in endometrial carcinoma. Oncol Rep, 36, 3405–3412.
40.
XuJ., TianS., YinZ., WuS., LiuL., QianY., et al. (2014a). MicroRNA-binding site SNPs in deregulated genes are associated with clinical outcome of non-small cell lung cancer. Lung Cancer, 85, 442–448.
41.
XuT., LiuX., HanL., ShenH., LiuL., and ShuY. (2014b). Up-regulation of miR-9 expression as a poor prognostic biomarker in patients with non-small cell lung cancer. Clin Transl Oncol, 16, 469–475.
42.
YangM., ShenH., QiuC., NiY., WangL., DongW., et al. (2013). High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer, 49, 604–615.
43.
YangW., ChendrimadaT.P., WangQ., HiguchiM., SeeburgP.H., ShiekhattarR., et al. (2006). Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat Struct Mol Biol, 13, 13–21.
44.
YuY., MaoL., ChengZ., ZhuX., CuiJ., FuX., et al. (2021). A novel regQTL-SNP and the risk of lung cancer: a multi-dimensional study. Arch Toxicol, 95, 3815–3827.
45.
YuY., MaoL., LuX., YuanW., ChenY., JiangL., et al. (2019). Functional Variant in 3′UTR of FAM13A Is Potentially Associated with Susceptibility and Survival of Lung Squamous Carcinoma. DNA Cell Biol, 38, 1269–1277.
46.
ZhanJ.F., ChenL.H., ChenZ.X., YuanY.W., XieG.Z., SunA.M., et al. (2011). A functional variant in microRNA-196a2 is associated with susceptibility of colorectal cancer in a Chinese population. Arch Med Res, 42, 144–148.
47.
ZhanY., LiangX., LiL., WangB., DingF., LiY., et al. (2016). MicroRNA-548j functions as a metastasis promoter in human breast cancer by targeting Tensin1. Mol Oncol, 10, 838–849.
48.
ZhangF., LiK., PanM., LiW., WuJ., LiM., et al. (2018). miR-589 promotes gastric cancer aggressiveness by a LIFR-PI3K/AKT-c-Jun regulatory feedback loop. J Exp Clin Cancer Res, 37, 152.
49.
ZhouM., WangH., ZengX., YinP., ZhuJ., ChenW., et al. (2019). Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 394, 1145–1158.
50.
ZhouM., WangX., ShiH., ChengL., WangZ., ZhaoH., et al. (2016). Characterization of long non-coding RNA-associated ceRNA network to reveal potential prognostic lncRNA biomarkers in human ovarian cancer. Oncotarget, 7, 12598–12611.
51.
ZhuanB., LuY., ChenQ., ZhaoX., LiP., YuanQ., et al. (2019). Overexpression of the long noncoding RNA TRHDE-AS1 inhibits the progression of lung cancer via the miRNA-103/KLF4 axis. J Cell Biochem, 120, 17616–17624.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
